🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Influence of Human Albumin Supplementation on Kidney Dysfunction After Liver Transplantation

RecruitingPhase 4Ages 18 Years - anyAllRennes University Hospital
NCT06535945 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

To verify whether albumin administration to achieve serum concentration above 30g/L (treated group) and its maintenance within plasmatic physiologic range (above 30 g/L) for five days diminishes rate of AKI at Day 7 after liver transplantation as compared to restrained albumin administration (when serum concentration is at 20 g/L or below (control)).

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Male and female subjects equal or above 18 yrs old. * Recipients of primary liver allografts from a deceased donor (including after cardiac death) and as a single organ (liver only). * Capability of understanding the purpose and risks of the study. * Written informed consent Exclusion Criteria: * Fulminant hepatitis * Kidney injury at baseline (Estimated Glomerular Filtration Rate \< 50 ml/min in Modification of diet in renal disease-6) including hepatorenal syndrome * Use of an induction agent Basiliximab at liver transplantation * Protected person (adults legally protected, under judicial protection, guardianship, or supervision), person deprived of their liberty
💊

What it tests

  • Albumin administration
📍

Where

8 sites
08_CHRU de Tours Hôpital Trousseau
Chambray-lès-Tours, France
03_APHP Hôpital Beaujon
Clichy, France
04_CHU de Lille Hôpital Huriez
Lille, France
05_HCL Hôpital de la Croix Rousse
Lyon, France
06_CHU de Montpellier Hôpital St Eloi
Montpellier, France
02_CHU de Bordeaux - Hôpital Haut Leveque
Pessac, France
01_CHU de Rennes Hôpital Pontchaillou
Rennes, France
09_APHP Hôpital Paul Brousse
Villejuif, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy